PLAUR and colorectal carcinoma: This would allow for an evaluation of the possibility of identifying individuals with a high risk for CRC adjusted for relevant clinical variables and to evaluate uPAR levels in association with other serological biomarkers such as carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1 (Nielsen et al, 2007).